web analytics


Discuva’s primary focus is to produce new safe antibiotics which are effective against the Multidrug-resistant (MDR) bacteria including Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae Escherichia coli and Neisseria gonorrhoeae to treat urinary tract and respiratory infections as well as sepsis and sexually-transmitted disease.

This not only addresses the large and growing nosocomial market but also provides treatment options for the increasing problems within the community. To circumvent the issues experienced with current classes of antibiotic, Discuva are applying the proprietary SATIN platform technology to screen for chemical classes which hit molecular targets distinct from those already known to interact with existing antibiotics.

Discuva’s approach seeks novel compound classes which have a narrower bacteriocidal spectrum of activity. This approach increases the potential number of bacterial targets available and ultimately reduces the risk of cross-resistance in the clinic. The platform has already been extensively validated by Discuva scientists against the current major antibiotic classes and under due diligence from collaboration partners.

Latest Tweets from @DiscuvaLtd

Discuva Ltd @DiscuvaLtd
RT @NASA: Bacteria may mutate more rapidly in space, helping to predict how pathogens become resistant to antibiotics: https://t.co/F8TwJ9a
Discuva Ltd @DiscuvaLtd
David Williams (CEO) @DiscuvaLtd will be presenting at #Superbugs & #Superdrugs on 21st March 2017 @SMi_Group
Discuva Ltd @DiscuvaLtd
RT @WHO: Great news! The @UN Secretary-General establishes the Interagency Coord. Group on #AntimicrobialResistance today https://t.co/c0EN